This Report Highlights How Companies Can Approach Clinical Trial Diversity
Black Doctor
Trinity Life Sciences’ recent white paper on diversity in clinical trials was mentioned in an article published on Black Doctor. Read Now…
FDA publishes updated draft guidance on clinical trial diversity
Fierce Biotech
Fierce Biotech mentioned Trinity Life Sciences’ recent white paper, Diversity in Clinical Trials: Life Sciences Initiatives and Challenges in Light of the FDA’s Latest Guidance, in their coverage of the updated FDA guidance. Read Now…
Mistrust in the healthcare system can hold trial diversity back, execs say: report
Fierce Biotech
Trinity Life Sciences’ recent white paper, Diversity in Clinical Trials: Life Sciences Initiatives and Challenges in Light of the FDA’s Latest Guidance, was featured in an article from Fierce Biotech highlighting how mistrust in the healthcare system is holding back trial diversity. Read Now…
Clinical Trial Diversity: Pharma Takes Action to Address Disparities
HIT Consultant
Trinity’s Lisa Bailey, Ph.D., Managing Director & Head of DEI Strategy, was featured in an article by HIT Consultant. Learn more about the importance of diverse clinical trial populations in achieving equitable healthcare. Read Now…
Aparna Deshpande, Head of Insights & Analytics at Trinity Life Sciences — Driving Pharmaceutical Innovation through Insights and Analytics
AI Time Journal
Aparna Deshpande, PhD, Trinity’s Head of Insights & Analytics, was featured in an interview with AI Time Journal. Read the article to learn more about driving pharmaceutical innovation through Insights and Analytics. Read Now…
One-third of health execs see mistrust hampering clinical trial diversity
MM+M
Trinity’s Lisa Bailey, Ph.D., Managing Director & Head of DEI Strategy, was featured in an article by MM+M. Learn about Trinity’s study on the most pressing challenges facing efforts to include more diverse patient populations in clinical trial research and what drugmakers can do at the corporate level to make a difference. Read Now…
Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills’
PharmaVoice
“When you look at the list of 50-plus FDA approvals [in 2023], we know from pattern recognition that there’s going to be winners and losers, and some who have to work harder for it — we’ve seen increasing difficulty of achieving success,” said Leslie Orne. Read more from Leslie Orne, Trinity Life Sciences’ President and CEO, in PharmaVoice‘s latest article on ‘Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills.’ Read Now…
Pfizer, Idorsia and AbbVie drug brands lead the way in pharma digital marketing — study
Endpoint News
The Annual Digital Marketing Competency Report was featured in Endpoint News. Read Now…
Reacting to Trends: Q&A With Leslie Orne, CEO of Trinity Life Sciences
Pharmaceutical Executive
Leslie Orne speaks with Pharmaceutical Executive about current trends in the life sciences industry and the ways that companies can react. Read Now…
Don’t Just Be an Armchair Leader: Interview with Leslie Orne, CEO of Trinity Life Sciences
Adam Mendler
Trinity’s President & CEO, Leslie Orne, sat down with Adam Mendler to discuss the significance of setting big goals, listening and leading by example. Read the interview to learn more. Read Now…